This trial is designed to determine if two procedures are better than one when it comes to treating patients with persistent or longstanding persistent atrial fibrillation. The aMAZE trial is studying the effectiveness of treating patients with left atrial appendage (LAA) closure followed by a pulmonary vein isolation (PVI) procedure to see if it reduces atrial fibrillation episodes more effectively compared to patients who only have a (PVI) ablation.
Our team performs the LARIAT® procedure. The innovative, LARIAT® suture device neatly ties a loop around the base of the LAA, closing off the small appendage from the heart to prevent blood clots from traveling to the brain. This is often performed for people with AFib who can’t take blood thinners.
Visit the SentreHEART aMAZE trial site or call 210-617-5300 ext. 14654 to see if you’re eligible to participate in this trial.
This trial is to measure the effectiveness of the NAVVUS RXi® catheter on the accurate measurement of blood flow before and following endovascular treatment for symptomatic lower extremity peripheral arterial disease, critical limb ischemia or claudication (a condition involving cramping in the leg after exercise often caused by a blockage in the arteries).
The study will use this type of catheter to document changes in the hemodynamics (blood flow) or translesional pressure gradients in patients with and without excess blood in the vessels for patients undergoing atherectomy, angioplasty or stenting of femoropopliteal and infrapoplieal lesions.
The study also includes more accurately measuring the ratio between the maximum achievable blood flow in a diseased coronary artery and the theoretical maximum flow in a normal coronary artery.
Visit the UT Health San Antonio trial site or call 210-617-5300 ext. 17035 to see if you’re eligible to participate in this trial.
This trial is to evaluate the effectiveness of the IASD® System II device in reducing the blood flow between the left and right atrium watching for the reduction of elevated pressure in the left atrium in patients diagnosed with diastolic heart failure.
Medications that work for other types of heart failure frequently aren’t effective for patients with this particular type of heart failure.
Candidates must be at least 40 years old. After meeting certain criteria and undergoing a bicycle exercise test, patients are randomly assigned to a treatment or control group. After two years, patients in the control group are allowed to cross over to the treatment group, if patient selection criteria are met at that time. Patients will be evaluated at pre-specified time intervals and followed for a five-year period.
Visit the Corvia Medical, Inc. site or call 210-450-9097 to see if you’re eligible to participate in this study.